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no significant difference.  Conclusion: Patients treated with 
BT or RP have similar QOL scores. QOL after BT is worse in the 
first year after treatment, but thereafter it is better than QOL 
after RP.  Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 The widespread use of prostate-specific antigen (PSA) 
for the detection of prostate carcinoma has led to an in-
crease in the number of patients who present with early-
stage disease. According to age, comorbidity, clinical
tumour stage, PSA and Gleason score, an individual 
treatment strategy is decided up by the patient and his 
physician  [1] . 
 Many patients are well-informed, and place impor-
tance not only on survival, but also their quality of life 
(QOL) after treatment  [2] . Indeed, studies have indicated 
that patients are even prepared to choose a therapy that 
offers a shorter life expectancy if it is associated with a 
better QOL  [3] .
 Compared to patients who receive brachytherapy 
(BT), those who undergo radical retropubic prostatecto-
my (RP) consider their disease more serious. The RP pa-
tient group believes more strongly that the treatment they 
choose offers the best chance of cure, whereas the BT
patient group believes that the method is less invasive,
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 Abstract 
 Objective: To evaluate quality of life (QOL) after radical ret-
ropubic prostatectomy (RP) and low-dose-rate brachythera-
py (BT).  Methods: Between 2001 and 2004, RP or BT was per-
formed in 212 patients. QOL data were evaluated with the 
European Organization for Research and Treatment of Can-
cer QLQ-C30 version 3.0, the International Prostate Symp-
tom Score (IPSS) and the International Index of Erectile Func-
tion-5 questionnaires. QOL data were compared.  Results: RP 
and BT were performed in 142 and 70 patients, respectively. 
The mean follow-up was 24 months (5–53). The mean overall 
global health score for patients after RP was 78 (0–100) and 
after BT it was 83 (33–100), and it showed a trend in favour of 
BT. The follow-up lasted at most 53 months, and the period 
was divided into yearly categories. Patients who underwent 
BT showed worse global health in the first year after opera-
tion, but thereafter they showed better health. Patients who 
received BT showed a trend towards having lower function-
al-scale and symptom-scale scores in the first year after op-
eration, and then higher scores for any subsequent year of 
follow-up. Only diarrhoea was temporarily worse in the sec-
ond year after BT compared to RP. The mean total IPSS and 
QOL score for BT and RP patients during follow-up showed 
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has fewer side effects, is less painful and is more conve-
nient  [4] .
 BT is considered to be a minimally invasive treatment 
alternative to RP or percutaneous radiotherapy for low-
risk prostate cancers. There is a growing interest among 
patients and physicians in this technique and it has been 
recently taken into evaluation for mandatory compensa-
tion by health-care insurance schemes in Switzerland. 
Data on intermediate- and long-term follow-up concern-
ing QOL after this relatively new technique are scarce. As 
the first institution offering BT in Switzerland (since 
2001), we felt it was timely to evaluate the intermediate-
term QOL of our patients.
 Patients and Methods 
 Patients 
 Consecutive patients with clinically localized prostate cancer 
who were treated at a single institution with radical RP (from 
January 2002 to December 2004, n = 142), or low-dose-rate BT 
(from March 2001 to December 2004, n = 70), had been prospec-
tively evaluated for general and oncological data (PSA value, bi-
opsy Gleason score, clinical tumour stage, perioperative compli-
cations, pathological tumour stage and tumour grade). This da-
tabase was used for contacting patients by mail. All patients were 
sent a set of questionnaires containing the European Organiza-
tion for Research and Treatment of Cancer QLQ-C30 version 3.0 
(EORTC QLQ-C30), the International Prostate Symptom Score 
(IPSS) and the International Index of Erectile Function-5 (IIEF-5) 
questionnaires. 
 Surgical and BT Techniques 
 Radical retropubic prostatectomy was performed in patients 
with disease that was defined clinically as being organ confined, 
and who had a negative computed tomogram of the pelvis and a 
negative bone scan. We used the standard RP technique, as de-
scribed by Walsh  [5] . The nerve-sparing technique was not rou-
tinely performed, but only done in select cases. Nerve sparing was 
only performed in preoperatively potent men with PSA  ! 10   g/l, 
who had unilateral cancer on biopsy and who wished to preserve 
potency (n = 14). Catheter removal was performed after 12 days if 
the cystogram showed an intact anastomosis.
 BT was performed as monotherapy in low- or intermediate-
risk patients (low risk was defined as PSA  ! 10 ng/ml, clinical 
stage T1c–T2a, Gleason score  ! 7; intermediate risk was either 
PSA 10–20 ng/ml or clinical stage T2b or Gleason score = 7), as 
recommended by the Swiss National Health Department. Only 
patients with a prostate  ! 60 ml, a urinary flow rate  1 10 ml/s and 
no significant residual urine were selected. Antiandrogen thera-
py, consisting of LH-RH analogs, was started in 11 patients with 
large glands preoperatively to down-size the gland or in patients 
who wanted to postpone the operation. Therapy was only admin-
istered once, for a duration of 3 months. 
 Iodine-125 seeds were implanted under general anaesthesia 
using a perineal template-guided loading technique under TRUS 
and radiologic guidance. The prescription dose was 145 Gy, in ac-
cordance with ABS recommendations  [6] . Intra-operative (‘real 
time’) planning was based on the TRUS images, the seed distribu-
tion was optimized for dose homogeneity and to keep organ dos-
es within limits (220 Gy for the urethra, and a maximum partial 
volume of 0.3 cm 3 of the rectal wall receiving the target dose of 
145 Gy). Post-operative dosimetry evaluation was based on com-
puted tomography and magnetic resonance imaging with image 
fusion.
 A Foley catheter was inserted at the beginning of the operation 
and generally removed on the day of surgery or on the first day 
after operation, when patients were discharged. All patients were 
administered tamsulosin postoperatively for a minimum of 8–12 
weeks. 
 Data Collection and Statistical Analysis 
 Data were entered into an excel file and statistical analysis per-
formed with SPSS 11.5 (SPSS Inc., Chicago, Ill., USA) statistical 
software package.
 Differences between means of the 2 groups were assessed with 
the Mann-Whitney U test. The Kruskal-Wallis test was used for 
statistical analysis of changes during follow-up within the groups. 
p  ! 0.05 was considered statistically significant. 
 In order to compare similar cases, patients were grouped into 
age categories: 40–55 (a1), 56–65 (a2), 66–75 (a3) and  1 75 years 
(a4). PSA values were grouped as 0–3.9 (p1), 4–10 (p2), 10.1–20 (p3) 
and  1 20 ng/ml (p4). Follow-up categories were 5–12 (f1), 13–24 
(f2), 25–36 (f3) and 37–53 (f4) months. 
 Results 
 RP was performed in 142 patients and BT was per-
formed in 70. In patients who answered the question-
naires, the mean age (range shown in parentheses) for RP 
was 64 years (47–75) and for BT it was 61 years (49–75,
p  ^  0.001). The mean PSA for RP was 11.3 ng/ml (0.3–24) 
and for BT it was 6.1 ng/ml (1.1–12.8, p  ^  0.001), the 
mean biopsy Gleason score for RP was 6.3 (5–9) and for 
BT it was 5.7 (4–7, p  ^  0.001). According to clinical risk 
categories, for RT and BT respectively, the number of pa-
tients at low risk were 27 and 39, at intermediate risk 24 
and 16, at high risk 54 and 0. 74% of RP patients and 79% 
of BT patients returned the questionnaires. The mean 
(range shown in parentheses) follow-up for RP was 20 
months (5–40) and for BT it was 28 months (8–53, p  ^  
0.001). Results were therefore categorized for follow-up 
length, age and PSA value. 
 The number of patients (total n = 160, overall response 
rate 75%) for age categories was 16 for a1, 74 for a2, 69 for 
a3 and 1 for a4. The number of patients for PSA categories 
was 22 for p1, 84 for p2, 41 for p3 and 13 for p4 and for 
follow-up it was 41 for f1, 49 for both f2 and f3, and 21
for f4.
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 The mean overall global health score for patients after 
RP and BT showed a trend (without statistical signifi-
cance) in favour of BT, with the score for RP patients be-
ing 78 (0–100) and that for BT patients being 83 (33–
100).
 When compared for follow-up periods f1–f4, there was 
a trend for BT patients to score worse in the first year af-
ter operation, but to score better for any subsequent year 
(without statistical significance). The results were also 
adjusted for patient age and PSA value by taking only the 
most frequent and comparable groups for analysis (i.e. a2 
and p2), and no change in QOL data could be found 
( fig. 1 ).
 Differences in functional scales for RP and BT patients 
were not significant for physical functioning, role func-
tioning, emotional functioning and social functioning 
(both overall and when adjusted for follow-up within 
groups and between different treatment groups). The 
only exception was cognitive functioning at 25–36
months (p = 0.029;  table 1 ). BT patients generally showed 
worse scores on functional scales in the first year after 
operation and better scores for the following years, com-
pared to RP patients.
 BT patients had significant changes in symptom scales 
over time for diarrhoea (p = 0.031), appetite loss (p = 
0.008), fatigue (p = 0.031), and nausea and vomiting (p = 
0.037). Differences between the 2 treatment groups were 
significant for diarrhoea for 13–24 months (p = 0.009), 
nausea and vomiting for 5–12 months (p = 0.026) and 
dyspnoea for 25–36 months (p = 0.005;  table 2 ).
 The mean total IPSS score and QOL score (IPSS 8) for 
BT and RP, adjusted for follow-up, showed no significant 
difference. The IIEF-5 sum showed a significant differ-
ence between BT and RP patients for 5–36 months of fol-
low-up. Considering a IIEF-5 sum of  6 20 as potent, we 
found 50% of patients after BT for f1 and f2 to be potent 
and 30% of patients for f3 and f4, regardless of pre-treat-
ment erectile function. 
 Discussion 
 For men faced with the diagnosis of prostate cancer a 
sometimes difficult decision-making process starts. The 
different curative treatment modalities, RP, BT or radio-
therapy (RT), have to be evaluated carefully. 
 Besides the oncologic outcome, QOL is of growing im-
portance for many patients. This issue needs to be dis-
cussed with patients when planning an individualized 
optimal treatment. Hall et al.  [7] found that for 40% of 
patients, a favourable side-effect profile is the main mo-
tivation to select BT. We therefore felt it was necessary to 
evaluate QOL in our patients to see whether these patient 
expectations are fulfilled. 
 At our centre we routinely offer RP, RT and BT to pa-
tients with localized prostate cancer. We have observed an 
increasing popularity for BT, partly because there is a per-
ception that side-effects, and therefore QOL, are better 
than after surgical management. BT is considered a mini-
mally invasive treatment option for patients with localized 
prostate cancer and most studies comparing different 
treatment modalities have focussed on acute and short-
term effects on QOL  [8–10] . Although our study also eval-
uates intermediate-term outcome after therapy, one of the 
drawbacks of our study is its retrospective design for eval-
uating QOL.  BT is currently under a nationwide prospec-
tive longitudinal evaluation for acute and late toxicity. 
 We found no statistically significant difference in 
overall global health after RP compared to BT, but data 
showed a trend for BT patients to score worse in the first 
year after operation and to be better for any later year of 
follow-up, compared to RP patients. When adjusted for 
follow-up length, age or pre-treatment PSA-level, no sig-
nificant differences in patients’ general QOL could be 
identified. Unfortunately, our sample size of patients is 
small. Further, we performed a retrospective cross-sec-
tional study and did not prospectively evaluate the QOL, 
which would have been more precise as this would have 
given us a personal baseline for each patient before treat-
ment and would have made significant changes in the 
QOL of each patient clearly visible. 
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 Fig. 1. Global health after RP and BT. 
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 Functional scales were similar after RP and BT, and 
again we found a similar pattern of BT patients scoring 
worse in the first year after operation and better there-
after. Symptom scales and items showed a significant 
change for patients treated with BT, with mainly gastro-
intestinal side effects reflecting the temporary toxicity of 
this technique and possibly also being a side effect of the 
administered tamsulosin medication. 
 Our findings are comparable with data in the recent 
literature ( table 3 ). Davis et al.  [11] compared RP, BT and 
RT in a cross-sectional study and found no difference in 
the overall QOL between BT and RP cohorts. Bacon et al. 
 [12] reported a cross-sectional analysis comparing RP, 
RT and BT. Compared with RP, RT was associated with 
significantly lower QOL scores, while no significant dif-
ferences were reported between RP and BT. BT was as-
sociated with poorer bowel function and worse bowel 
complaints.
 Interestingly, no investigator could find a clearly better 
general QOL after BT compared to the other treatment 
modalities, although some aspects were favourable for this 
technique. These findings are confirmed by our study. 
 Urinary morbidity has been reported to have a severe 
impact on QOL. In our study we found no significant dif-
ference in IPSS for BT patients compared to RP patients. 
The IPSS is designed to evaluate symptoms from benign 
prostatic hyperplasia and does not record incontinence, 
therefore the data from patients after RP have to be inter-
preted with care. We believe that the level of urinary tox-
icity after BT is reflected adequately by the IPSS. In the 
questionnaire recently released by the EORTC, the pros-
tate module (PR-25) is designed to evaluate urinary symp-
toms including incontinence, and could therefore be bet-
ter for evaluating the impact of different treatment mo-
dalities on urinary function for future studies.
 In a prospective study, Fulmer et al.  [17] evaluated 
voiding function after RP and BT with hormonal thera-
Table 1. Global health and functional scales after RP and BT
5–12 months 
n = 21 (12/9)
13–24 months 
n = 20 (11/9)
25–36 months 
n = 14 (8/6)
37–53 months 
n = 8 (5/3)
p within 
groups
p between 
groups
Global health
Prostatectomy 71.7827.4 78.1824.0 80.6811.4 77.889.6 NS
Brachytherapy 58.3835.4 85.0812.3 87.587.0 90.087.0 NS
Overall 67.9827.4 81.9818.1 84.089.7 85.489.7 NS
Cognitive functioning
Prostatectomy 80.0813.9 75.0830.9 88.9813.6* 88.9819.2 NS
Brachytherapy 33.3823.6 95.088.1 97.286.8* 93.389.1 NS
Overall 66.7827.2 86.1823.0 93.1811.1* 91.7812.6 0.029
Emotional functioning
Prostatectomy 68.3832.5 74.0837.6 91.789.1 88.9812.7 NS
Brachytherapy 54.2841.2 85.8817.6 93.1811.1 90.0814.9 NS
Overall 64.3832.2 80.6828.0 92.489.7 89.6813.2 NS
Physical functioning
Prostatectomy 97.386.0 90.8823.4 95.686.9 97.883.8 NS
Brachytherapy 76.7833.0 97.384.7 98.982.7 100.080.0 NS
Overall 91.4817.5 94.4815.7 97.285.3 99.282.4 NS
Role functioning
Prostatectomy 80.0827.4 95.8811.8 97.286.8 100.080.0 NS
Brachytherapy 66.7847.1 95.0811.2 100.080.0 100.080.0 NS
Overall 76.2830.2 95.4811.2 98.684.8 100.080.0 NS
Social functioning
Prostatectomy 76.7825.3 81.3825.9 86.1812.5 77.8838.5 NS
Brachytherapy 58.3835.4 91.7814.2 91.7813.9 90.0814.9 NS
Overall 71.4826.7 87.0820.3 88.9813.0 85.4824.3 NS
All values are means 8 SD.
p values within groups according to the Kruskal-Wallis test and between groups according to the Mann-Whitney U test.
* Significant difference between treatment groups.
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py. They found a significant increase in total American 
Urological Association Symptom Score after BT, and only 
after RP did patients return to near-baseline scores again. 
For urinary continence 42% of patients after RP and 75% 
after BT had returned to baseline at 12 months. Miller et 
al.  [16] compared long-term outcome after RP, RT and 
BT. They found a significant improvement in irritative 
and obstructive symptoms a median of 6.2 years after BT, 
whereas urinary incontinence QOL worsened. In patients 
after RP, no QOL changes over this time period were ob-
served. Comparing RP and BT  [10–12, 14] , most authors 
found urinary symptoms or bother to be worse after BT, 
but continence was generally better. Concerning QOL, it 
remains controversial whether irritative and obstructive 
voiding symptoms or incontinence is of more concern for 
the individual patient. According to our results, the im-
pact on urinary function and general QOL seems to be 
similar for both treatment modalities. 
Table 2. Symptom scales and single items after RP and BT
5–12 months 
n = 21 (12/9)
13–24 months 
n = 20 (11/9)
25–36 months 
n = 14 (8/6)
37–53 months 
n = 8 (5/3)
p within 
groups1
p between 
groups2
Appetite
Prostatectomy 0.080.0 4.2811.8 0.080.0 0.080.0 NS
Brachytherapy 33.3847.1 0.080.0 0.080.0 0.080.0 0.008
Overall 9.5825.2 1.987.9 0.080.0 0.080.0 NS
Constipation
Prostatectomy 40.0843.5 12.5817.3 5.6813.6 11.1819.2 NS
Brachytherapy 33.3847.1 3.3810.5 0.080.0 0.080.0 NS
Overall 38.1840.5 7.4814.3 2.889.6 4.2811.8 NS
Diarrhoea
Prostatectomy 20.0818.3 4.2811.8* 16.7827.9 0.080.0 NS
Brachytherapy 0.080.0 13.3817.2* 0.080.0 6.7814.9 0.031
Overall 14.3817.8 9.3815.4* 8.3820.7 4.2811.8 0.009
Dyspnoea
Prostatectomy 6.7814.9 8.3815.4 5.6813.6* 0.080.0 NS
Brachytherapy 33.3847.1 0.080.0 0.080.0* 6.7814.9 NS
Overall 14.3826.2 3.7810.8 2.889.6* 4.2811.8 0.005
Fatigue
Prostatectomy 15.6814.9 19.4829.5 5.689.3 0.080.0 NS
Brachytherapy 44.4862.9 10.0813.3 4.687.4 6.789.9 0.031
Overall 23.8831.7 14.2821.8 5.188.0 4.288.3 NS
Financial difficulties
Prostatectomy 0.080.0 20.8830.5 5.6813.6 0.080.0 NS
Brachytherapy 50.0823.6 10.0822.5 0.080.0 20.0844.7 NS
Overall 14.3826.2 14.8826.1 2.889.6 12.5835.4 NS
Nausea and vomiting
Prostatectomy 0.080.0* 6.3817.7 0.080.0 0.080.0 NS
Brachytherapy 8.3811.8* 0.080.0 2.886.8 0.080.0 0.037
Overall 2.486.3* 2.8811.8 1.484.8 0.080.0 0.026
Pain
Prostatectomy 16.7823.6 8.3823.6 0.080.0 0.080.0 NS
Brachytherapy 33.3847.1 3.387.0 8.3813.9 0.080.0 NS
Overall 21.4828.4 5.6816.2 4.2810.4 0.080.0 NS
Insomnia
Prostatectomy 13.3818.3 20.8830.5 5.6813.6 0.080.0 NS
Brachytherapy 16.7823.6 13.3817.2 5.6813.6 6.7814.9 NS
Overall 14.3817.8 16.7823.6 5.6813.0 4.2811.8 NS
All values are means 8 SD.
p values within groups according to the Kruskal-Wallis test and between groups according to the Mann-Whitney U test.
* Significant difference between treatment groups. 
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 QOL is becoming an important issue for our well-in-
formed patients with prostate cancer when evaluating the 
different treatment options together with their physician. 
Gwede et al.  [4] could show that patients who received BT 
chose this treatment because of QOL considerations, 
whereas ‘cure’ and complete removal of the tumour was 
the main motivation for patients selecting RP.
 Interestingly, BT and RP have similar QOL outcome 
on intermediate-term follow-up. In the first year after op-
eration there is a trend in favour of RP, but for the follow-
ing years scores are better for BT.
 We have to admit that our study has a selection bias. 
Patients receiving BT were younger with more favourable 
tumour characteristics than those undergoing RP. But 
this reflects our strict policy of only performing BT as 
Table 3. Recent literature on comparison of QOL after treatment for localized prostate cancer
Authors Year Number per method Follow-
up
Type of study questionnaire Results
RP BT RT
Miller
et al. [16]
2005      general 709 6.2 years Prospective longitudinal
RAND SF-12
EPIC-26
General: no differences
Urinary: BT improvement irritative-obstructive,
BT/RT worsened incontinence, RP no changes
Sexual: RT worsened, RP no changes
Borchers
et al. [8]
2004 801 52 – 1 year Prospective longitudinal 
EORTC QLQ C-30 
ICS male incontinence
Kelly
General: no differences
Urinary: RP most bothersome incontinence
Sexual: RP worse, BT only minor change
Bradley
et al. [14]
2004 60 1542 – 19–30 
months
Cross-sectional
FACT-G, AUA-SS
Brief sexual function inventory
General: no differences
Urinary: BT worse symptoms, BT better continence
Sexual: BT initially better function, does not persist over time
Downs
et al. [15]
2003 327 92 – 18–21 
months
Prospective longitudinal
RAND SF-36
UCLA PCI
General: no differences
Urinary: BT better function, bother no difference
Sexual: BT and RP decreases in function
Wei
et al. [13]
2002 896 114 2033 n.a. Cross-sectional
RAND SF-36
FACT-G/FACT-P, EPIC
General: all worse compared to healthy volunteers
Urinary: RP and BT worse
Sexual: BT worse
Bacon
et al. [12]
2001 421 69 2214 13–32 
months
Cross-sectional
CARES SF
RAND SF-36
General: BT and RP no differences, RT worse
Urinary: BT better function and worse bother than RP
Sexual: BT better function, less bother than RP
Davis
et al. [11]
2001 269 142 222 22–38 
months
Cross-sectional
RAND SF-36
UCLA PCI
General: BT and RP no differences
Urinary: RP worse
Sexual: RP worse
Lee
et al. [10]
2001 23 44 23 1 year Prospective longitudinal
FACT-G/FACT-P
IPSS
General: BT and RP/RT no differences
Urinary: BT worse symptoms
Sexual: n.a.
Krupski
[9]
2000 27 1112 – 1 year Cross-sectional
FACT-G, IPSS
Urinary function questionnaire
for men
Brief sexual function inventory
General: BT monotherapy and RP no difference
Improvement over time; BTC worse, decline over time
Urinary: RP lowest IPSS, better irritative and obstructive 
symptoms
Sexual: BTM and RP improvement over time; BTC decline
over time
EPIC = Expanded Prostate Cancer Index Composite; ICS = International Continence Society; FACT-G/P = Functional Assessment of Cancer Ther-
apy General/Prostate; AUA-SS = American Urological Association Symptom Score; UCLA PCI = UCLA Prostate Cancer Index; EPIC = Expanded Pros-
tate Cancer Index Composite; CARES SF = Cancer Rehabilitation Evaluation System Short Form; n.a. = not available .
1 Perineal radical prostatectomy, 38 with nerve sparing compared to 42 without nerve sparing. 
2 Comparing BT monotherapy and BT combined with external beam radiotherapy (BTC). 
3 All groups compared to matched healthy volunteers. 
4 Compared to hormonal therapy (n = 33) and watchful waiting (n = 31).
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monotherapy without external beam radiotherapy or 
hormonal manipulation in low- and intermediate-risk 
patients. As no information on biochemical recurrence 
and following adjuvant treatment was collected, the im-
pact of this on QOL cannot be estimated, but it could 
represent a bias of the study. When patients were adjusted 
for age and PSA value, no significant difference in out-
come of any treatment modality could be found. Some 
QOL symptom scales such as nausea, vomiting and dys-
pnoea are presumably not related to the intervention but 
to the individual patient’s comorbidities. Further, pa-
tients’ comorbidities were not recorded, and they could 
bias our study as they influence QOL.
 Of course, prospective randomized trials would be de-
sirable for a non-biased evaluation. However, as most pa-
tients are well-informed, they wish to decide themselves 
which treatment to choose and want their physician to 
provide them with the relevant information. Therefore, it 
is important for any physician counselling patients with 
localized prostate cancer to know about health-related 
QOL data for the different treatment modalities. 
 Conclusions 
 Patients treated with BT have worse global health, 
functional scales and symptom scales in the first year af-
ter treatment and score better than RP patients in most 
domains thereafter. Gastrointestinal symptoms are tem-
porarily more prominent after BT compared to RP.
 Further studies are needed to prospectively evaluate 
long-term QOL for the treatment of localized prostate 
cancer.
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